Enhanced  ||| S:0 E:9 ||| NNP
Retinal  ||| S:9 E:17 ||| NNP
Ganglion  ||| S:17 E:26 ||| NNP
Cell  ||| S:26 E:31 ||| NNP
Survival  ||| S:31 E:40 ||| NNP
in  ||| S:40 E:43 ||| IN
Glaucoma  ||| S:43 E:52 ||| NNP
by  ||| S:52 E:55 ||| IN
Hypoxic  ||| S:55 E:63 ||| NNP
Postconditioning  ||| S:63 E:80 ||| NNP
After  ||| S:80 E:86 ||| IN
Disease  ||| S:86 E:94 ||| NNP
Onset  ||| S:94 E:100 ||| NNP
The  ||| S:100 E:104 ||| DT
neuroprotective  ||| S:104 E:120 ||| JJ
efficacy  ||| S:120 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
adaptive  ||| S:132 E:141 ||| JJ
epigenetics ||| S:141 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
wherein  ||| S:154 E:162 ||| JJ
beneficial  ||| S:162 E:173 ||| JJ
gene  ||| S:173 E:178 ||| NN
expression  ||| S:178 E:189 ||| NN
changes  ||| S:189 E:197 ||| NNS
are  ||| S:197 E:201 ||| VBP
induced  ||| S:201 E:209 ||| VBN
by  ||| S:209 E:212 ||| IN
nonharmful  ||| S:212 E:223 ||| JJ
conditioning  ||| S:223 E:236 ||| NN
stimuli ||| S:236 E:243 ||| NNS
,  ||| S:243 E:245 ||| ,
is  ||| S:245 E:248 ||| VBZ
now  ||| S:248 E:252 ||| RB
well  ||| S:252 E:257 ||| RB
established  ||| S:257 E:269 ||| VBN
in  ||| S:269 E:272 ||| IN
several  ||| S:272 E:280 ||| JJ
acute ||| S:280 E:285 ||| NN
,  ||| S:285 E:287 ||| ,
preclinical  ||| S:287 E:299 ||| JJ
central  ||| S:299 E:307 ||| JJ
nervous  ||| S:307 E:315 ||| JJ
system  ||| S:315 E:322 ||| NN
injury  ||| S:322 E:329 ||| NN
models ||| S:329 E:335 ||| NNS
.  ||| S:335 E:337 ||| .
Recently ||| S:337 E:345 ||| RB
,  ||| S:345 E:347 ||| ,
in  ||| S:347 E:350 ||| IN
a  ||| S:350 E:352 ||| DT
mouse  ||| S:352 E:358 ||| NN
model  ||| S:358 E:364 ||| NN
of  ||| S:364 E:367 ||| IN
glaucoma ||| S:367 E:375 ||| NN
,  ||| S:375 E:377 ||| ,
we  ||| S:377 E:380 ||| PRP
demonstrated  ||| S:380 E:393 ||| VBD
retinal  ||| S:393 E:401 ||| JJ
ganglion  ||| S:401 E:410 ||| JJ
cell  ||| S:410 E:415 ||| NN
( ||| S:415 E:416 ||| -LRB-
RGC ||| S:416 E:419 ||| NNP
)  ||| S:419 E:421 ||| -RRB-
protection  ||| S:421 E:432 ||| NN
by  ||| S:432 E:435 ||| IN
repetitively  ||| S:435 E:448 ||| JJ
preconditioning  ||| S:448 E:464 ||| NN
with  ||| S:464 E:469 ||| IN
hypoxia  ||| S:469 E:477 ||| JJ
prior  ||| S:477 E:483 ||| JJ
to  ||| S:483 E:486 ||| TO
disease  ||| S:486 E:494 ||| NN
onset ||| S:494 E:499 ||| NN
,  ||| S:499 E:501 ||| ,
indicating  ||| S:501 E:512 ||| VBG
an  ||| S:512 E:515 ||| DT
epigenetic  ||| S:515 E:526 ||| JJ
approach  ||| S:526 E:535 ||| NN
may  ||| S:535 E:539 ||| MD
also  ||| S:539 E:544 ||| RB
yield  ||| S:544 E:550 ||| VB
benefits  ||| S:550 E:559 ||| NNS
in  ||| S:559 E:562 ||| IN
chronic  ||| S:562 E:570 ||| JJ
neurodegenerative  ||| S:570 E:588 ||| JJ
disease ||| S:588 E:595 ||| NN
.  ||| S:595 E:597 ||| .
Herein ||| S:597 E:603 ||| NNP
,  ||| S:603 E:605 ||| ,
we  ||| S:605 E:608 ||| PRP
determined  ||| S:608 E:619 ||| VBD
whether  ||| S:619 E:627 ||| IN
presenting  ||| S:627 E:638 ||| VBG
the  ||| S:638 E:642 ||| DT
repetitive  ||| S:642 E:653 ||| JJ
hypoxic  ||| S:653 E:661 ||| JJ
stimulus  ||| S:661 E:670 ||| NN
after  ||| S:670 E:676 ||| IN
disease  ||| S:676 E:684 ||| NN
initiation  ||| S:684 E:695 ||| NNS
[ ||| S:695 E:696 ||| -LRB-
repetitive  ||| S:696 E:707 ||| FW
hypoxic  ||| S:707 E:715 ||| FW
postconditioning  ||| S:715 E:732 ||| FW
( ||| S:732 E:733 ||| -LRB-
RH-Post ||| S:733 E:740 ||| NNP
) ||| S:740 E:741 ||| -RRB-
]  ||| S:741 E:743 ||| -RRB-
could  ||| S:743 E:749 ||| MD
afford  ||| S:749 E:756 ||| VB
similar  ||| S:756 E:764 ||| JJ
functional  ||| S:764 E:775 ||| NN
and  ||| S:775 E:779 ||| CC
morphologic  ||| S:779 E:791 ||| JJ
protection  ||| S:791 E:802 ||| NN
against  ||| S:802 E:810 ||| IN
glaucomatous  ||| S:810 E:823 ||| JJ
RGC  ||| S:823 E:827 ||| NNP
injury ||| S:827 E:833 ||| NN
.  ||| S:833 E:835 ||| .
Chronic  ||| S:835 E:843 ||| JJ
elevations  ||| S:843 E:854 ||| NNS
in  ||| S:854 E:857 ||| IN
intraocular  ||| S:857 E:869 ||| JJ
pressure  ||| S:869 E:878 ||| NN
( ||| S:878 E:879 ||| -LRB-
IOP ||| S:879 E:882 ||| NNP
)  ||| S:882 E:884 ||| -RRB-
were  ||| S:884 E:889 ||| VBD
induced  ||| S:889 E:897 ||| VBN
unilaterally  ||| S:897 E:910 ||| RB
in  ||| S:910 E:913 ||| IN
adult  ||| S:913 E:919 ||| JJ
male  ||| S:919 E:924 ||| JJ
C57BL ||| S:924 E:929 ||| CD
/ ||| S:929 E:930 ||| CD
6  ||| S:930 E:932 ||| CD
mice  ||| S:932 E:937 ||| NNS
by  ||| S:937 E:940 ||| IN
episcleral  ||| S:940 E:951 ||| JJ
vein  ||| S:951 E:956 ||| NN
ligation ||| S:956 E:964 ||| NN
.  ||| S:964 E:966 ||| .
Mice  ||| S:966 E:971 ||| NNS
were  ||| S:971 E:976 ||| VBD
randomized  ||| S:976 E:987 ||| VBN
to  ||| S:987 E:990 ||| TO
an  ||| S:990 E:993 ||| DT
RH-Post  ||| S:993 E:1001 ||| JJ
[ ||| S:1001 E:1002 ||| -LRB-
1  ||| S:1002 E:1004 ||| CD
h  ||| S:1004 E:1006 ||| NN
of  ||| S:1006 E:1009 ||| IN
systemic  ||| S:1009 E:1018 ||| JJ
hypoxia  ||| S:1018 E:1026 ||| NNS
( ||| S:1026 E:1027 ||| -LRB-
11 ||| S:1027 E:1029 ||| CD
%  ||| S:1029 E:1031 ||| NN
oxygen ||| S:1031 E:1037 ||| NN
)  ||| S:1037 E:1039 ||| -RRB-
every  ||| S:1039 E:1045 ||| DT
other  ||| S:1045 E:1051 ||| JJ
day ||| S:1051 E:1054 ||| NN
,  ||| S:1054 E:1056 ||| ,
starting  ||| S:1056 E:1065 ||| VBG
4  ||| S:1065 E:1067 ||| CD
days  ||| S:1067 E:1072 ||| NNS
after  ||| S:1072 E:1078 ||| IN
IOP  ||| S:1078 E:1082 ||| NNP
elevation ||| S:1082 E:1091 ||| CD
]  ||| S:1091 E:1093 ||| -RRB-
or  ||| S:1093 E:1096 ||| CC
an  ||| S:1096 E:1099 ||| DT
untreated  ||| S:1099 E:1109 ||| JJ
control  ||| S:1109 E:1117 ||| NN
group ||| S:1117 E:1122 ||| NN
.  ||| S:1122 E:1124 ||| .
After  ||| S:1124 E:1130 ||| IN
3  ||| S:1130 E:1132 ||| CD
weeks  ||| S:1132 E:1138 ||| NNS
of  ||| S:1138 E:1141 ||| IN
experimental  ||| S:1141 E:1154 ||| JJ
glaucoma ||| S:1154 E:1162 ||| NN
,  ||| S:1162 E:1164 ||| ,
the  ||| S:1164 E:1168 ||| DT
21-27 ||| S:1168 E:1173 ||| JJ
%  ||| S:1173 E:1175 ||| NN
reduction  ||| S:1175 E:1185 ||| NN
and  ||| S:1185 E:1189 ||| CC
5-25 ||| S:1189 E:1193 ||| CD
%  ||| S:1193 E:1195 ||| NN
prolongation  ||| S:1195 E:1208 ||| NN
in  ||| S:1208 E:1211 ||| IN
flash  ||| S:1211 E:1217 ||| JJ
visual-evoked  ||| S:1217 E:1231 ||| JJ
potential  ||| S:1231 E:1241 ||| JJ
amplitudes  ||| S:1241 E:1252 ||| NN
and  ||| S:1252 E:1256 ||| CC
latencies ||| S:1256 E:1265 ||| NN
,  ||| S:1265 E:1267 ||| ,
respectively ||| S:1267 E:1279 ||| RB
,  ||| S:1279 E:1281 ||| ,
and  ||| S:1281 E:1285 ||| CC
the  ||| S:1285 E:1289 ||| DT
30 ||| S:1289 E:1291 ||| CD
%  ||| S:1291 E:1293 ||| NN
impairment  ||| S:1293 E:1304 ||| NN
in  ||| S:1304 E:1307 ||| IN
visual  ||| S:1307 E:1314 ||| JJ
acuity  ||| S:1314 E:1321 ||| NN
were  ||| S:1321 E:1326 ||| VBD
robustly  ||| S:1326 E:1335 ||| RB
improved  ||| S:1335 E:1344 ||| VBN
in  ||| S:1344 E:1347 ||| IN
RH-Post-treated  ||| S:1347 E:1363 ||| JJ
mice ||| S:1363 E:1367 ||| NNS
,  ||| S:1367 E:1369 ||| ,
as  ||| S:1369 E:1372 ||| RB
was  ||| S:1372 E:1376 ||| VBD
the  ||| S:1376 E:1380 ||| DT
17 ||| S:1380 E:1382 ||| CD
%  ||| S:1382 E:1384 ||| NN
loss  ||| S:1384 E:1389 ||| NN
in  ||| S:1389 E:1392 ||| IN
RGC  ||| S:1392 E:1396 ||| NNP
soma  ||| S:1396 E:1401 ||| JJ
number  ||| S:1401 E:1408 ||| NN
and  ||| S:1408 E:1412 ||| CC
20 ||| S:1412 E:1414 ||| CD
%  ||| S:1414 E:1416 ||| NN
reduction  ||| S:1416 E:1426 ||| NN
in  ||| S:1426 E:1429 ||| IN
axon  ||| S:1429 E:1434 ||| JJ
integrity ||| S:1434 E:1443 ||| NN
.  ||| S:1443 E:1445 ||| .
These  ||| S:1445 E:1451 ||| DT
protective  ||| S:1451 E:1462 ||| JJ
effects  ||| S:1462 E:1470 ||| NNS
were  ||| S:1470 E:1475 ||| VBD
observed  ||| S:1475 E:1484 ||| VBN
without  ||| S:1484 E:1492 ||| IN
RH-Post  ||| S:1492 E:1500 ||| JJ
affecting  ||| S:1500 E:1510 ||| VBG
IOP ||| S:1510 E:1513 ||| NNP
.  ||| S:1513 E:1515 ||| .
The  ||| S:1515 E:1519 ||| DT
present  ||| S:1519 E:1527 ||| JJ
findings  ||| S:1527 E:1536 ||| NNS
demonstrate  ||| S:1536 E:1548 ||| VBP
that  ||| S:1548 E:1553 ||| DT
functional  ||| S:1553 E:1564 ||| NN
and  ||| S:1564 E:1568 ||| CC
morphologic  ||| S:1568 E:1580 ||| JJ
protection  ||| S:1580 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
RGCs  ||| S:1594 E:1599 ||| NNP
can  ||| S:1599 E:1603 ||| MD
be  ||| S:1603 E:1606 ||| VB
realized  ||| S:1606 E:1615 ||| VBN
by  ||| S:1615 E:1618 ||| IN
stimulating  ||| S:1618 E:1630 ||| VBG
epigenetic  ||| S:1630 E:1641 ||| JJ
responses  ||| S:1641 E:1651 ||| NNS
during  ||| S:1651 E:1658 ||| IN
the  ||| S:1658 E:1662 ||| DT
early  ||| S:1662 E:1668 ||| JJ
stages  ||| S:1668 E:1675 ||| NNS
of  ||| S:1675 E:1678 ||| IN
disease ||| S:1678 E:1685 ||| NN
,  ||| S:1685 E:1687 ||| ,
and  ||| S:1687 E:1691 ||| CC
thus  ||| S:1691 E:1696 ||| RB
constitute  ||| S:1696 E:1707 ||| VB
a  ||| S:1707 E:1709 ||| DT
new  ||| S:1709 E:1713 ||| JJ
conceptual  ||| S:1713 E:1724 ||| JJ
approach  ||| S:1724 E:1733 ||| NN
to  ||| S:1733 E:1736 ||| TO
glaucoma  ||| S:1736 E:1745 ||| VB
therapeutics ||| S:1745 E:1757 ||| NNS
.  ||| S:1757 E:1759 ||| .
